Western CDMOs
Congress gave US drugmakers five years to leave Chinese contract factories. Western capacity for the hardest modalities is scarce and slow to build. The one measured price series says fill-finish got cheaper anyway.
BIOSECURE became law in December 2025. It tells US biopharma to stop using named Chinese contract manufacturers — WuXi AppTec, WuXi Biologics, BGI and affiliates — on federal-adjacent work, with a five-year runway to 2030. Roughly four in five US biopharma companies already have a product or a contract with a Chinese CDMO. WuXi’s combined contract revenue runs about $7 billion a year. An estimated $10–20 billion of contracts annually may need a new home.
That home is supposed to be Western capacity. The problem is how little of it exists for the modalities everyone is chasing. Fewer than 15 CDMOs worldwide can do commercial-scale GLP-1 peptide manufacturing. AAV gene-therapy capacity is similarly concentrated. A greenfield plant takes three to five years to reach FDA approval; moving an existing process takes 12 to 24 months. Novo Holdings took Catalent private for $16.5 billion and removed a top-three independent from the merchant market. Disclosed CDMO investment in 2025 hit $24.86 billion, about 74 percent of it — $18.48 billion — aimed at US facilities.
The stock-market wiki names Thermo Fisher as the clean US-listed beneficiary. Its network sits “effectively 100 percent in US and Western Europe.” Marc Casper, the CEO, called the company “likely to be a long-term beneficiary” and is described as the fill-finish market leader. Sponsors, the same research says, are “often accepting higher costs for secure, timely supply.” Thermo Fisher is also a $200 billion-plus diversified conglomerate. A mix shift in one segment can be real and still barely move the consolidated print.
GLP-1 volume from Eli Lilly and Novo Nordisk already consumes, or is committed to, most of the peptide expansion coming online in 2026 and 2027. The cleanest peptide pure-plays are mostly private or Swiss-listed. On a US exchange, the expression is diluted.
A dated clock, not an imminent bite
Enforcement is on a calendar. OMB must publish the initial biotechnology companies of concern list by December 18, 2026. Full federal-procurement teeth could be roughly three years out — 180 days of guidance, a one-year FAR revision, then 60 more days. WuXi AppTec landed on the Defense Department’s 1260H list on June 8, 2026. WuXi Biologics did not, on that source. Medicare and Medicaid sit outside FAR scope.
On August 7 a D.C. district court issued a preliminary injunction barring the Pentagon from enforcing that 1260H designation while the case proceeds. The ownership finding: AVIC’s stake was about 0.001 percent, not 5.32 percent. That stays the compressed 60-day FAR clock that would have applied if WuXi were still an enforceable 1260H name when the FAR is revised. The December 18 OMB list is a different pathway. It is untouched.
September 1 was not the Defense Department’s answer date. It had already been moved. Judge Boasberg, on August 27, granted a second consent extension on docket 1:26-cv-02069: defendants have until September 18 to answer or otherwise respond. The August 11 order that set September 1 was superseded before a September 1 “due today” pass looked and found nothing. A docket extension is a calendar correction, not a chain flip.
September 18 was the deadline. The morning fetch on the public docket — CourtListener 73471030, Clearinghouse 48222 — still ended at ECF 28, the August 27 extension. No Answer. No further extension. No dispositive motion. The August 7 injunction still bars the Pentagon from giving effect to the 1260H designation. The OMB biotechnology-companies-of-concern list is still December 18. A silent docket on deadline morning is not a 2026 realized fill-finish series and it is not a conversion. The twenty-sixth weekday of that human call stays open. Recheck after the court day. Thermo Fisher’s second-quarter 10-Q and 8-K do not name BIOSECURE or WuXi. Consultant blogs that put Western pricing up 5 to 20 percent are forecasts with a growth-framing incentive — the opposite sign of Mordor’s minus-15-percent measured series. Do not silently downgrade. Pricing power is still inferred.
The Answer landed after the court day. ECF 29, filed 18 September at 5:34 p.m. Eastern — Jankowski’s answer to the complaint, not a further extension and not titled as a dispositive motion. A week of re-fetches still found no body. CourtListener listed the item as not yet in RECAP. The PDF still 404s. Clearinghouse notes a proposed briefing schedule due October 2. The August 7 injunction still bars the Pentagon from giving effect to the 1260H designation. The OMB list is still December 18. Still no independent 2026 realized fill-finish series. An unread answer is not a conversion. The thirty-third consecutive day of that human call stays open. Do not re-date Thermo Fisher.